Physician profile
Caitlin C Walker
NPI 1225534761
$3,274.86
in general payments reported to CMS, 2019-2025
27 companies · $856 in 2025
The $856 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2022: $205 · 2023: $924 · 2024: $1,163 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $432.12 | 2023-2025 | Brexafemme, Blujepa |
| Abbvie INC. | $390.03 | 2019-2025 | Lo Loestrin Fe, Liletta |
| Organon LLC | $286.23 | 2022-2025 | Nexplanon, Nuvaring |
| Mayne Pharma Commercial LLC | $260.01 | 2022-2025 | |
| Hologic Sales and Service, LLC | $227.44 | 2023-2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Bayer Healthcare Pharmaceuticals INC. | $224.34 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $218.63 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $174.65 | 2023-2025 | Slynd |
| Coopersurgical, INC. | $166.59 | 2023-2025 | Paragard T 380a, Summit Doppler, Sos |
| Astellas Pharma US INC | $136.55 | 2023-2025 | Veozah |
| Biogen, INC. | $133.68 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $71.56 | 2024-2025 | |
| Evofem Biosciences, INC. | $64.01 | 2023 | Phexxi |
| Medtronic, INC. | $63.76 | 2025 | Interstim |
| Aspira Women'S Health INC | $59.82 | 2022-2024 | Ova1 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $59.43 | 2023 | Myrisk |
| Baxter Healthcare | $58.04 | 2023-2025 | Tisseel |
| Pfizer INC. | $50.79 | 2024-2025 | |
| Millicent US INC | $36.52 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Ethicon US, LLC | $32.85 | 2023 | Stratafix, Harmonic |
| Minerva Surgical, INC | $22.19 | 2024 | |
| Merck Sharp & Dohme LLC | $20.48 | 2024 | Gardasil, Gardasil 9 |
| Myovant Sciences INC. | $20.19 | 2022 | |
| Gynesonics, INC. | $18.51 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Avion Pharmaceuticals | $18.31 | 2022 | |
| Lilly USA, LLC | $14.10 | 2025 | Zepbound |
| Exact Sciences Corporation | $14.03 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.